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Abstract: B a c k g r o u n d: There are contradictory results from studies on the effect of curcumin, 
a plant phenolic compound with a well-established anticancer effect in vitro, on the action of etopo-
side in cancer cells. 
O b j e c t i v e: The aim of this study was to evaluate the influence of curcumin on the genotoxic and 
cytostatic action of etoposide in the LT12 cell line derived from BN rat acute myeloid leukemia cells. 
M a t e r i a l  &  M e t h o d s: The LT12 cells were treated with different doses of curcumin for 1–72 
hours followed by application of etoposide. The amount of DNA damage was estimated via a comet 
assay. Viability, cell cycle and apoptosis were examined by using flow cytometry technique. 
R e s u l t s: The combined effect of curcumin and etoposide on viability was synergistic at low micro-
molar concentrations. In comparison to treatment with curcumin and etoposide alone, co-treatment 
with these compounds increased the extent of DNA damage, the percentage of cells arrested in the 
G2/M phase and the number of annexin-V-positive cells. 
C o n c l u s i o n s: The interaction between etoposide and curcumin points to an enhanced antileukemic 
potential to be derived from the combination of these compounds.
Key words: curcumin, etoposide, apoptosis, cell cycle, DNA damage.
INTRODUCTION
Conventional chemotherapeutics used for treatment of leukemia stimulate apop-
tosis of leukemic cells but, due to defects in apoptotic signaling pathways, the-
re are some cells which are resistant to cytostatic-induced apoptosis [1]. Acute 
myeloid leukemia (AML), a disease of myeloid progenitor cells, primarily affects 
the elderly, because the incidence of this leukemia increases significantly after 
65 years of age. Paradoxically, it is the most difficult disease to treat in this age 
group [2]. Elderly patients have co-morbid conditions and do not tolerate the ag-
gressive chemotherapy which is necessary to obtain positive therapeutic effects [2]. 
Younger patients, i.e. under 65 years of age, achieve initial remission in about 
80% of cases, but most of them relapse [3]. Therefore, further research is being 
conducted into more effective and less aggressive treatments for this leukemia.
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The research is focused in particular on natural ingredients with potential 
anticancer properties. Some of these ingredients are plant polyphenols. These 
compounds have more selective toxicity to cancer cells than to their normal coun-
terparts and can reduce cytostatic side effects [4, 5]. Data have been published 
regarding the antiproliferative and proapoptotic effect on cancer cells of polyphe-
nols, among them curcumin, the most active component of turmeric (Curcuma 
longa) [6]. Polyphenol curcumin can act selectively in cancer cells with high levels 
of free radicals, increasing their oxidative stress which leads to apoptosis, whereas 
it has a much lower toxicity to normal cells with reduced oxidative stress [7, 8].
One cytostatic frequently used as a first-line drug for treatment of a wide 
range of cancers such as various types of leukemia is etoposide. It is used to-
gether with other anticancer drugs and irradiation [9]. The anticancerous acti-
vity of etoposide depends on both DNA strand cleavage through stabilization of 
a DNA-topoisomerase II cleavable complex and direct or indirect DNA modifica- 
tion [10]. The DNA-topoisomerase II- etoposide complex disables the re-ligation 
reaction and relaxation. This results in permanent DNA breaks leading to induc-
tion of the apoptotic signaling pathway. Etoposide also inhibits G2 phase of the 
cell cycle and increases ROS level in leukemia cells [11, 12]. 
The effect of the prooxidative action of etoposide in myeloid leukemia cells co-
uld be enhanced by co-administration of curcumin, taking into account the fact 
that cancer cells are much more sensitive to oxidative DNA damage compared 
to normal cells [7]. The genotoxic and proapoptotic action of curcumin towards 
leukemia cells has been demonstrated by in vitro experiments [13]. Curcumin can 
induce apoptosis by caspase activation and cytochrome c release [14]. 
The combined effect of curcumin and etoposide on the LT12 cell line derived 
from Brown Norway rat acute myeloid leukemia (BNML) was tested in the pres-
ent study. BNML leukemia cells have a similar sensitivity to chemotherapy as 
human AML cells [15]. Moreover, BNML leukemia is accompanied by oxidative 
stress [16] similar to human leukemia [17, 18]. Thus, rat leukemic cells are 
a good model for the study of compounds with potential anticancer activity. 
The effect of curcumin on the cytostatic action of etoposide in leukemic cells 
is not very well known. The main goal of the present study was a determination 
of the effect of curcumin on the genotoxic and cytostatic action of etoposide in 
the LT12 cell line. The influence of curcumin on the DNA damage induced by 
etoposide was evaluated by comet assay. Cell cycles and the final effect of cyto-
static action, apoptosis and necrosis were investigated using multicolor staining 
and flow cytometry. 
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MATERIAL AND METHODS
CHEMICALS
Curcumin, etoposide, normal and low melting point (LMPA) agarose, triton-X-100, 
ethylenediamine tetraacetc acid disodium salt (EDTA), propidium iodide (PI), ri-
bonuclease A were acquired from Sigma-Aldrich Co. (USA) and dimethyl sulfoxi-
de (DMSO) was from POCH (Poland). The medium (RPMI 1640), serum (FBS), 
phosphate-buffered saline (PBS) were purchased from PAA (Germany). Annexin 
V-FITC was from Roche (Germany).
CELL CULTURE AND TREATMENT
LT12 cells (supplied by Professor A.C.M. Martens, Utrecht) were cultured in RPMI 
1640 supplemented with 10% FCS and antibiotics (100 U/ml penicillin and 
100 μg/ml streptomycin). Cells were incubated at 37°C in a 5% CO2 and 95% 
humidified atmosphere and kept in the logarithmic growth phase. 
LT12 cells were seeded in 24-well culture plates at a density of 1×106 cells/ml 
and incubated in the presence of different concentrations of curcumin and/or 
etoposide for 1–48 hours. Polyphenol and etoposide were dissolved in 1% ethanol 
in PBS. Control cells were incubated only in the presence of vehicles. 
MEASUREMENTS OF VIABILITY
To determine the viability after treatment, the cells were incubated for 48 hours 
in a concentration range of 1–40 μM and 1–100 μM for etoposide and curcumin, 
respectively. After incubation, the cells were washed twice in PBS. One million cel-
ls were resuspended in 100 μl of PBS with propidium iodide (PI) (2.5 μg/ml) and 
incubated for 10 minutes in the dark. Then, the cells were immediately analyzed 
by flow cytometry (Becton Dickinson, Biosciences Immunocytometry Systems, San 
Jose, CA, USA). Analysis was performed on at least 20 000 single cells. CalcuSyn 
(Biosoft, Cambridge, UK) software was used in the calculation of ED50 and the 
combination index (CI). The CI was evaluated based on the multiple drug-effect 
equation of Chou-Talalay [19]. CI values <1, = 1, and >1 indicate synergism, an 
additive effect, and antagonism, respectively.
MEASUREMENTS OF DNA DAMAGE USING AN ALKALINE COMET ASSAY
The cells were incubated for one hour in a concentration range of 0.25–2.0 μM and 
1–20 μM for etoposide and curcumin, respectively. The extent of DNA dama-
ge was determined by alkaline single cell gel electrophoresis, according to Tice 
et al. [20]. Briefly, 5 μl of cells in PBS was mixed with 75 μl of 0.5% low melting 
point agarose. The mixture was pipetted into slides precoated with 0.5% normal 
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melting point agarose, covered with a coverglass and put on ice to allow the 
agarose to solidify. After 5 minutes, the slides were placed for 24 h at 4oC into 
lysis solution (2.5 M NaCl, 100 mM EDTA, 10 mM Tris, pH 10.0 and 1% Triton 
X-100, 10% DMSO) added freshly before use. The slides were then washed with 
Tris-HCL, pH 7.5 and placed in a horizontal electrophoresis tank containing fresh 
electrophoresis buffer (300 mM NaOH, 1 mM EDTA, pH 13) and incubated for 
40 min at 4oC. Electrophoresis was carried out for 30 min in a cold room at 
0.74 V/cm and 300 mA. The slides were then washed with Tris-HCL, pH 7.5, 
stained with propidium iodide (2.5 μg/ml) and analyzed using a fluorescence 
microscope (Olympus CX-40; Olympus, Tokyo, Japan). An image system (The 
Comet Score™ image analysis system, TriTek Corporation, Sumerduck, Virginia, 
USA) was used for the measurement of percentage of DNA in the tail of comets. 
Two slides per rat, with 100 randomly selected comets per slide, were analyzed. 
CELL CyCLE ANALySiS
The quantity of cells in different phases of the cell cycle and sub-G1 fraction 
were evaluated upon staining with propidium iodide. Briefly, cells were washed 
with PBS, fixed in cold 70% ethanol and stored at –20oC. After fixation, the cells 
(2 × 106 cells) were washed in PBS and incubated for 30 min in 0.5 ml of solution 
containing: 0.1% Triton X-100, 20 mg RNAse A and 2% Pi. The cell cycle was 
analyzed via a flow cytometry using CellQuest software (Becton-Dickinson, BD 
Biosciences immunocytometry Systems, San Jose, CA, USA). 
QUANTifiCATiON Of APOPTOTiC CELLS USiNG AN ANNEXiN V BiNDiNG ASSAy
Apoptotic cells were detected using an Annexin V-fLUOS staining kit. The cells 
were resuspended in binding HEPES buffer at a concentration of 1 × 106 cells/100 
μl. The cells were incubated in the dark with 2 μl Annexin V-fiTC and 2 μl Pi 
for 15 min and analyzed via a flow cytometry (Becton-Dickinson, BD Biosciences 
immunocytometry Systems, San Jose, CA, USA) for green (fiTC) and red (Pi) 
fluorescence. Apoptosis was examined using CellQuest software. Early apoptotic 
cells were defined as annexin V-positive and Pi-negative, while late apoptotic and/
or necrotic cells were annexin V- and Pi-positive. Results were expressed as the 
percentage of apoptotic cells (Annexin V-positive cells) in samples from treated 
cells versus the controls.
STATiSTiCAL ANALySiS
Values were expressed as means ± SEM. A one-way analysis of variance (p <0.05) 
and Tukey’s post hoc test were used to determine significant differences between 
control and experimental samples. 
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RESULTS
Viability of LT12 cells after treatment with curcumin and/or etoposide. The via-
bility of control LT12 cells was 97%. EC50 values were 8.3 μM and 47.7 μM for 
etoposide and curcumin, respectively. Analysis of CI revealed that lower concen-
trations of curcumin (15.8–67.7 μM) and etoposide (1.8–13 μM) exert synergistic 
interaction. Antagonistic interaction was observed at the higher concentrations 
of curcumin (above 70 μM) and etoposide (above 13 μM). The synergistic effect 
was observed for most of the combinations (Fig. 1).
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Fig. 1. The influence of combination of curcumin and etoposide on viability of LT-12 cells.  
The cells were incubated for 48 hours with curcumin (1–100 µM) and etoposide (1–40 µM).  
Then, the cells were stained with propidium iodide and the viability was measured by using  
a flow cytometry. CI — Combination index.
DNA damage. Etoposide induced a dose-dependent increase in DNA damage 
compared with the control (Fig. 2a). Curcumin did not induce significant DNA 
damage in the concentration range 1–10 μM, whereas incubation with the exam-
ined polyphenol at a dose of 20 μM led to a significant increase in DNA damage 
in comparison to the control cells (Fig. 2b). A significant increase in the DNA 
damage induced by etoposide was observed after pre-incubation with curcumin 
at doses of 10 and 20 μM (Fig. 2a). Pre-incubation with lower doses of curcumin 
(1–5 μM) did not significantly influence the extent of DNA damage induced by 
etoposide. 
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Fig. 2. The proportion of DNA strand breaks induced by etoposide (a), curcumin and combination of 
tested compounds (b) in LT-12 cells. DNA damage was measured by using comet assay. 
(c) Representative photographs show DNA strand breaks obtained by comet assay. Scale bar — 
5 μM. C — curcumin, E — etoposide. p* <0.05 vs. control, p** <0.01 vs. control, p*** <0.001 vs. 
control, p# <0.05 vs. etoposide, p## <0.01 vs. etoposide, p### <0.001 vs. etoposide. 
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Influence of curcumin on cell cycle. Curcumin administration significantly 
increased the number of cells in the G2/M at the dose of 10 and 20 μM after 72 
hours in comparison to the control (Fig. 3a). A significant increase in the sub-G1 
population (subdiploidal fraction) was observed 48 and 72 hours after curcumin 
administration at a dose of 20 μM (Fig. 3b). 
The impact of etoposide at a dose of 2 μM on a cell cycle depended on the 
arrest of the cells in the G2/M phase after 72 hours (Fig. 3c). The sub-G1 frac-
tion increased significantly after etoposide treatment of the cells with 48 and 72 
hours of incubation (Fig. 3d). Pre-incubation of the cells with curcumin signifi-
cantly increased the number of cells arrested by etoposide in the G2/M phase 
after 48 and 72 h compared to etoposide applied alone (Fig. 3c). Treatment with 
polyphenol and etoposide led to a significant enhancement of the sub-G1 fraction 
induced by the cytostatic after 72 hours of incubation in comparison to etoposide 
alone (Fig. 3d). 
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Fig. 3. The influence of curcumin and/or etoposide treatment on cell cycle of LT-2 cells. After in-
cubation, the cells were stained with propidium iodide and DNA content was measured by using 
a flow cytometry. The percentage of cells in G2/M phase (a) and sub-G1 fraction (b) after curcumin 
treatment. C — curcumin, E — etoposide. p* <0.05 vs. control, p** <0.01 vs. control, p*** <0.001 vs. 
control, p# <0.05 vs. etoposide, p## <0.01 vs. etoposide.
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Fig. 4. The apoptosis of LT-12 cells induced by curcumin and/or etoposide after 48 and 72 hours of 
incubation. (a, b) Early and late apoptosis after incubation of LT-12 cells with curcumin. (c, d) Early 
and late apoptosis after coincubation with curcumin and etoposide. (e) Representative dot-plots of 
annexin V-FITC (FL1) vs. PI (FL3) are shown. C — curcumin, E — etoposide. p* <0.05 vs. control, 
p** <0.01 vs. control, p*** <0.001 vs. control, p# <0.05 vs. etoposide, p## <0.01 vs. etoposide. 
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Influence of curcumin on the apoptosis of LT12 cells. Curcumin applied at 
doses of 1–10 μM did not exert any significant proapoptotic effect in comparison 
with the control cells for 48–72 h, whereas incubation of LT12 cells with cur-
cumin at a dose of 20 μM significantly increased the number of early apoptotic 
(An+) and/or late apoptotic (An+/PI+) cells compared to the control (Fig. 4a, b). 
Etoposide significantly induced apoptosis in each time series. Pre-incubation with 
curcumin at a dose of 5 μM for 48 h and 72 h significantly increased the proap-
optotic effect of etoposide (Fig. 4c–e). 
DISCUSSION
The effect of curcumin on the activity of etoposide is not yet well understood. 
There is evidence of a synergistic action between this polyphenol and etoposide 
in brain tumor cell lines [21]; however, there are some studies suggesting anta-
gonism between curcumin and this chemotherapeutic in breast and uterus can-
cer cell lines [22]. Curcumin protected these last cancer cells against apoptosis 
caused by etoposide and induced DNA damages repair. 
The results of the present study confirm that curcumin can enhance the effect 
of etoposide in acute myeloid leukemia cells leading to an increase in apoptosis. 
Moreover, the influence of a combination of the tested compounds on the viability 
of LT-12 cells was synergistic at lower concentrations. It may be supposed that the 
influence of curcumin on etoposide action can depend on the type of cancer cells.
Other research suggests that curcumin can cause damage to DNA and inhibit 
cell cycles of cancer cells using a variety of mechanisms depending on the type 
of cells [23]. The present study indicates that, at a concentration of 20 μM, cu-
rcumin induces significant DNA damage in LT12 cells after 1 hour of incubation. 
The concentrations of 10 and 20 μM of this polyphenol also significantly increased 
the extent of DNA strand breaks induced by etoposide. These results are consis-
tent with studies by Lu et al. [24], who showed that curcumin has a genotoxic 
effect on colorectal carcinoma HCT116 cells at a concentration of 50 μM after 
1 h incubation. However, in human hepatoma HepG2 cells, curcumin causes 
significant damage to the DNA in nuclear and mitochondrial genomes from con-
centrations of 10 μM after 1 hour incubation [25]. It can be assumed that the 
curcumin-generated ROS plays an important role in causing DNA damage. It is 
well documented that ROS can directly lead to double strand breaks [26].
DNA damage caused by curcumin may contribute to the observed cell cycle 
arrest in the G2/M phase and the increase in the percentage of the sub-G1 
fraction. These results are consistent with other studies that have shown that 
curcumin arrests the cell cycle precisely in this phase in different cell lines [27]. 
Similar effects on the cell cycle are exerted by etoposide. Co-treatment of cells 
with curcumin and etoposide led to an increase in the level of G2/M arrest in 
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comparison to each compound alone. Treatment of the cells with curcumin and 
etoposide also resulted in an increase in the sub-G1 fraction, which may indicate 
the presence of apoptotic cells. Other studies have shown that the effect of cur-
cumin on cell cycle arrest involves the use of various mechanisms, e.g. causation 
of spindle abnormalities, DNA damge, chomosomal alteration or topoisomerase 
poisoning [24, 27, 28].
A curcumin concentration of 20 μM was effective in inducing apoptosis of 
LT-12 cells. This polyphenol can exert apoptotic effect by inducing oxidative stress. 
The other studies showed that curcumin induced apoptosis and increased ROS 
level in HL-60 cells at concentrations of 10–20 μM and its â-diketone structure 
played a role in the prooxidative activity [29]. Curcumin reduced the transition 
metal ions which led to the activation of molecular oxygen. 
In this study, curcumin increased the externalization of phosphatidylserine 
induced by etoposide. These results correlate with an increase in the sub-G1 
fraction after simultaneous incubation with the test compounds, pointing to the 
complementary action of curcumin asserted together with this cytostatic. Other 
studies have demonstrated that curcumin can increase the effects of some cy-
tostatics, e.g. cisplatin, paclitaxel, vincristine, doxorubicin, in various types of 
cancer cells [30–33]. 
Leukemia cells are characterized by abnormal proliferation and apoptosis, 
which predisposes them to prolonged survival [1, 34]. Curcumin hits the vario-
us molecular targets of cells of hematological malignancies, e.g. NFkB, STAT, 
p38 MAPK, bax, ornithine decarboxylase and mTOR, leading to inhibition of the 
proliferation and sensitization of the these cells to apoptosis [23]. Curcumin may 
therefore in many ways sensitize leukemia cells to the action of etoposide. 
CONCLUSIONS
The present study indicates for the first time, that the combination of curcumin 
and etoposide can have a beneficial therapeutic effect on myeloid leukemia cells. 
The antineoplastic action of curcumin relied on DNA damage, arresting cell cycles 
and inducing apoptosis of impaired LT12 cells. Further studies are necessary to 
clarify the mechanism of action of the combination of curcumin and etoposide 
in different cell lines of acute myeloid leukemia.
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